Reading Room

Recommendations for Contraceptive Use

Previous PageNext PageTable Of Contents


Combined Injectable Contraceptives


Q.3. When can the next injection be provided?

Recommendations

Rationale

a) The best time to provide the next injection is on the same date each month (or a 4 week schedule may be practical for some programs). This should be emphasized when training the personnel and counseling the clients.

The grace period of combined injectable contraceptives (CICs) is officially 3 days. If a client comes in after the grace period (33 days after the previous injection), advise her that delays in obtaining injections increase the risk of pregnancy. Offering re-injection for a woman who comes in after the grace period is reasonable for a woman who states that, once beyond the grace period, she has been abstaining or consistently using a back-up method, or if the provider can be reasonably sure that the woman is not pregnant. Some programs will advise the woman to use a back-up method for 7 days.

a) Clinical trials have studied the efficacy of CICs given 27 to 33 days after the previous injection and found the efficacy to be very high. Some studies have found that the risk of ovulation is low up to 60 days after the previous Cyclofem or Mesigyna injection.
  1. Sang G. Pharmacodynamic effects of once-a-month combined injectable contraceptives. Contraception 1994;49(4):361-85.
  2. Aedo AR, Landgren BM, Johannisson E, Diczfalusy E. Pharmacokinetic and pharmacodynamic investigations with monthly injectable contraceptive preparations. Contraception 1985;31(5):453-69.
  3. Bassol S, Garza-Flores J. Review of ovulation return upon discontinuation of once-a-month injectable contraceptives. Contraception 1994;49(5):441-53.
   
b) The fetus will be exposed to the injectable's hormones if the woman is pregnant when she receives the next injection.

However, there is no evidence that fetal exposure to CICs will be harmful.

b) Although the estrogens and progestins in CICs have no known teratogenic effects, avoiding fetal exposure is preferable on general principles.
  1. Simpson JL, Phillips OP. Spermicides, hormonal contraception and congenital malformations. Advances in Contraception 1990;6:141-67.
  2. Bracken MB. Oral contraception and congenital malformations in offspring: a review and meta-analysis of the prospective studies. Obstetrics and Gynecology 1990;76:552-7.
   
c) It is acceptable to give the injection if you can be reasonably sure she is not pregnant.

Any part of Recommendations for Updating Selected Practices in Contraceptive Use may be reproduced or adapted to meet local needs without prior permission from the TG/CWG Secretariat, provided the TG/CWG is acknowledged and the material is made available free of charge or at cost.


| Home | Family Planning | Maternal & Neonatal Health | Cervical CancerRelated Health Topics
Tools for Trainers
| Reading Room | Related Links | Search ReproLine | Website Tools

Quick Search 

Website design copyright © 1995-2003 by JHPIEGO Corporation. All rights reserved.

Last Updated: 09 Jul 2003

URL: http://www.reproline.jhu.edu/
Reproductive Health Online (ReproLine): a family planning and reproductive health training website

Top Of Page